On Tuesday, Editas Medicine Inc (NASDAQ: EDIT) opened higher 2.82% from the last session, before settling in for the closing price of $1.77. Price fluctuations for EDIT have ranged from $0.91 to $6.22 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 9.50% annually for the last half of the decade. Company’s average yearly earnings per share was noted 36.08% at the time writing. With a float of $82.94 million, this company’s outstanding shares have now reached $83.71 million.
In an organization with 246 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 85.89%, operating margin of -590.68%, and the pretax margin is -805.8%.
Editas Medicine Inc (EDIT) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Editas Medicine Inc is 0.93%, while institutional ownership is 54.29%. The most recent insider transaction that took place on Jun 03 ’25, was worth 37,400. Before that another transaction happened on Mar 04 ’25, when Company’s EVP, CHIEF FINANCIAL OFFICER sold 4,109 for $1.71, making the entire transaction worth $7,030. This insider now owns 112,720 shares in total.
Editas Medicine Inc (EDIT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 36.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.11% during the next five years compared to -1.48% drop over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Check out the current performance indicators for Editas Medicine Inc (EDIT). In the past quarter, the stock posted a quick ratio of 3.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.04, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.13 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Let’s dig in a bit further. During the last 5-days, its volume was 1.88 million. That was inferior than the volume of 3.06 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 63.62%. Additionally, its Average True Range was 0.17.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 38.08%, which indicates a significant decrease from 78.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 104.74% in the past 14 days, which was lower than the 159.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4271, while its 200-day Moving Average is $2.1736. However, in the short run, Editas Medicine Inc’s stock first resistance to watch stands at $1.9067. Second resistance stands at $1.9933. The third major resistance level sits at $2.1167. If the price goes on to break the first support level at $1.6967, it is likely to go to the next support level at $1.5733. The third support level lies at $1.4867 if the price breaches the second support level.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
There are currently 83,713K shares outstanding in the company with a market cap of 152.36 million. Presently, the company’s annual sales total 32,310 K according to its annual income of -237,090 K. Last quarter, the company’s sales amounted to 4,660 K and its income totaled -76,090 K.
